The last day of operation for Hertfordshire and West Essex ICB was 31 March 2026. The information on this website has not been updated since 31 March 2026. The legacy policies, prescribing recommendations and pathways can be accessed on this website. Find out more

RAG rating
n/a
Document type
Clinical pathways
Place
Hertfordshire and West Essex ICB
Output type
Clinical Pathways
Pathway
LUTS Pathway

Male LUTS

Pathway published: June 2024.
Next review date: June 2026.
 
 Lower urinary tract symptoms (LUTS) can be grouped into storage, voiding, and post-micturition symptoms.
    • Storage symptoms include urgency, daytime urinary frequency, nocturia, and urinary incontinence. 
    • Voiding symptoms include slow stream, splitting or spraying, straining, intermittency, hesitancy, straining, and terminal dribbling. 
    • Post-micturition symptoms include post-micturition dribble and the sensation of incomplete emptying. 

  • Lower urinary tract symptoms (LUTS) in men can be caused by:
    • Structural or functional abnormalities in one or more parts of the lower urinary tract (the bladder, bladder neck, prostate, urethral sphincter, and urethra).
    • Abnormalities of the peripheral or central nervous system that affect control of the bladder and sphincter.
    • Cardiovascular, respiratory, renal, or endocrine conditions that affect the production of urine.

  • Most elderly men have at least one LUTS; however, symptoms are often mild or not very bothersome.
  • Benign prostatic enlargement is a common cause of LUTS. Other causes include neurological conditions (such as dementia and diabetic neuropathy), infection, injury to the urethral area, drugs (such as diuretics and antimuscarinics), and cancer.

  • An assessment of men with suspected LUTS should include:
    • Taking a history of symptoms and severity, asking about possible underlying causes, sexual function, lifestyle habits, emotional and psychological factors.
    • Reviewing current medication.
    • Offering a physical examination, and examining the abdomen, external genitalia, performing a digital rectal examination, and examining the perineum and/or lower limbs. 
    • Asking men with bothersome LUTS to complete a urinary frequency-volume chart for at least 3 days.
    • Excluding serious causes of LUTS.  

  • Investigations should be guided by the symptoms, history, and examination but may include:
    • A dipstick test of the urine to check for blood, glucose, protein, leucocytes, and nitrites.
    • Serum creatinine and estimated glomerular filtration rate (eGFR) should be measured if clinically indicated.
    • A prostate-specific antigen (PSA) test if appropriate.

  • Men considering any treatment for LUTS should be offered an assessment of their baseline symptoms with a validated symptom score, such as the International Prostate Symptom Score (IPSS), to allow assessment of subsequent symptom change. 

  • Management of LUTS includes:
    • Excluding (and managing) serious causes of LUTS.
    • Providing tailored information and advice. 
    • Offering drug treatment to men with bothersome LUTS if conservative management is unsuccessful or inappropriate. 
      • An alpha-blocker for men with moderate to severe LUTS.
      • A 5-alpha reductase inhibitor for men with LUTS who have prostates estimated to be larger than 30 g or a PSA level greater than 1.4 ng/ml, and who are considered to be at high risk of progression.
      • An antimuscarinic for men with symptoms of overactive bladder or mirabegron if an antimuscarinic is contraindicated, not effective, or not tolerated.
      • A loop diuretic or oral desmopressin for men with nocturnal polyuria.
      • Combination treatments where appropriate. 
    • Regularly reviewing treatment to re-assess symptoms, quality of life, and assess adverse effects.   
    • Arranging specialist referral if appropriate. 
 

 
Please see pathway attached. 
Back